There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
Results for performance period 4 of the Oncology Care Model just came out; what are the initial takeaways?
Practices that consistently have performed well continued to perform well. Practices that were trending in the right direction, but maybe haven’t made savings, a few of our practices have made savings, they made it over that finish line, and we’ve set that expectation that that is likely to happen given the good work that they were doing, and they’re seeing those results. And practices that haven’t performed well consistently, no surprise, didn’t get a very good report card with this reconciliation.
About half of our practices earned a PBP [performance-based payment] by this period, which is a performance period 4. That’s an increase in what we saw since performance period 3, which was about a third of our customer base earned a savings payment.
So, that was exciting news. I think overall, practices are happy with the results. I’m seeing a lot of smiling faces based on those results here, at [the Quality Cancer Care Alliance Fall 2019 Leadership Summit], which is great. But they’re a high-performing group, so they’re biased in that way, as they’re more progressive and stronger performing than some of the other practices that we work with. But good results overall, I think.
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More